IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy
Oct 24, 2019
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer
Oct 02, 2019
Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).
Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?
Jan 31, 2019
Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.
Imugene Meets All Endpoints in Phase 1b Gastric Cancer Immuno-oncology Trial: Tumour Reduction In Gastric Cancer
Dec 17, 2018
Imugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.
Canada Legalises Cannabis as CPH Moves Front and Centre With a 100% Owned Canadian Growing Facility
Oct 18, 2018
This week, Canada has become the second country in the world — and the first industrialised nation — to legalise recreational cannabis use nationwide. ASX cannabis innovator, Creso Pharma (ASX:CPH), has welcomed this change with open arms.
ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment
Oct 16, 2018
Duchenne muscular dystrophy (DMD) is a rare, yet fatal, muscular genetic condition that affects one in 3600 to 6000 male births worldwide. This ASX junior, capped at just $7 million, is already in a Phase II clinical trial with its flagship drug to treat DMD.